Show Summary Details
Page of

Hallucinogens and dissociative drugs 

Hallucinogens and dissociative drugs
Chapter:
Hallucinogens and dissociative drugs
DOI:
10.1093/med/9780198714750.003.0015
Page of

PRINTED FROM OXFORD MEDICINE ONLINE (www.oxfordmedicine.com). © Oxford University Press, 2016. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 14 December 2018

Chapter 15 of Addiction Medicine covers hallucinogens and dissociative drugs. Hallucinogens are a large and diverse group of substances, some of which occur in fungi and plants and some which are chemically synthesized. Psychostimulants described in this chapter include psilocybin, mescaline, ayahuasca, lysergic acid diethylamide (LSD), and NBOMes and tryptamines. Dissociative drugs include ketamine, phencyclidine (PCP), and nitrous oxide. The prevalence and mode of use of these drugs is described together with their pharmacological effects. The clinical syndromes of acute intoxication and chronic use, flashbacks, psychosis, acute anxiety state, and acute and chronic brain syndromes are described, flashbacks being particularly characteristic of this group. Management of the acute toxicity syndrome is outlined. It is noted that dependence does not occur on most hallucinogens, although is described for ketamine.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.